Clinical study of S-1 alone compared to gemcitabine combined with S-1 in treatment of patients with advanced pancreatic cancer
10.3760/cma.j.issn.1006-9801.2015.05.008
- VernacularTitle:替吉奥单药及其联合吉西他滨治疗晚期胰腺癌的临床观察
- Author:
Lina ZHOU
;
Liqiang WANG
;
Haiyuan XU
;
Zhangyi JI
;
Min TANG
;
Minbin CHEN
- Publication Type:Journal Article
- Keywords:
Pancreatic neoplasms;
S-1;
Gemcitabine
- From:
Cancer Research and Clinic
2015;27(5):328-331
- CountryChina
- Language:Chinese
-
Abstract:
Objective To value the clinical efficacy and toxicity of S-1 compared to gemcitabine combined with S-1 in treatment of patients with advanced pancreatic cancer.Methods From January 2011 to December 2013,the data of 46 patients with advanced pancreatic cancer were analyzed retrospectively,including 24 patients receiving S-1 alone (group A) and 22 patients who received gemcitabine combined with S-1 (group B).The results were evaluated by objective response rate (ORR),disease control rate (DCR),survival time and safety.Results In group A the ORR was 20.8 ％ (5/24),DCR was 66.7 ％ (16/24),median progression-free survival was 4.8 months,median overall survival was 9.6 months,and 1 year survival was 12.5 ％.In group B the ORR was 27.3 ％ (6/22),DCR was 72.7 ％ (16/22),median progression-free survival was 5.9 months,median overall survival was 10.3 months,and 1 year survival was 22.7 ％.There was no significant difference between the two groups (P ＞ 0.05).The incidence rates of leukopenia,neutropenia and thrombopenia in group A were significantly lower than those in group B (P ＜ 0.05).Conclusion S-1 alone and gemcitabine combined with S-1 have similar effects in the treatment of advanced pancreatic cancer,but the toxicity of S-1 is mild and tolerable.
